儿童甲型肝炎减毒活疫苗的免疫原性和耐受性综述。
A review of immunogenicity and tolerability of live attenuated Hepatitis A vaccine in children.
作者信息
Rao Sameer, Mao J S, Motlekar Salman, Fangcheng Zhuang, Kadhe Ganesh
机构信息
a Medical Affairs Department , Wockhardt Ltd , Bandra (East), Mumbai , India.
b Institute of Viral Diseases, Zhejiang Academy of Medical Sciences , Hangzhou , China.
出版信息
Hum Vaccin Immunother. 2016 Dec;12(12):3160-3165. doi: 10.1080/21645515.2016.1216286.
Abstract
Changing epidemiology of Hepatitis A virus (HAV) has led to an increased susceptibility of adolescents and adults to the infection. Vaccination can remarkably reduce the incidence and associated morbidity of HAV infection. This review is focused on the safety and efficacy of H2 strain derived live attenuated Hepatitis A vaccine. We found the vaccine to be highly immunogenic with minimal or negligible safety issues. Moreover, a single dose of live attenuated vaccine persists a long term immune response and can be a preferred option for developing countries. In 2014, Indian Academy of Paediatrics (IAP) also updated their recommendations for H2 vaccine as a single dose as against the previous 2 dose schedule. A focused approach to include the vaccine in national immunization program should be explored.
摘要
甲型肝炎病毒（HAV）流行病学的变化导致青少年和成人对该感染的易感性增加。接种疫苗可显著降低HAV感染的发病率及相关发病情况。本综述聚焦于H2株甲型肝炎减毒活疫苗的安全性和有效性。我们发现该疫苗具有高度免疫原性，安全性问题极少或可忽略不计。此外，单剂量减毒活疫苗可产生长期免疫反应，对于发展中国家而言可能是一个首选选项。2014年，印度儿科学会（IAP）也将其对H2疫苗的推荐更新为单剂量，而非之前的两剂次接种程序。应探索一种有针对性的方法将该疫苗纳入国家免疫规划。
相似文献
1
A review of immunogenicity and tolerability of live attenuated Hepatitis A vaccine in children.
Hum Vaccin Immunother. 2016 Dec;12(12):3160-3165. doi: 10.1080/21645515.2016.1216286.
2
Comparison of the safety and immunogenicity of live attenuated and inactivated hepatitis A vaccine in healthy Chinese children aged 18 months to 16 years: results from a randomized, parallel controlled, phase IV study.
Clin Microbiol Infect. 2016 Sep;22(9):811.e9-811.e15. doi: 10.1016/j.cmi.2016.06.004. Epub 2016 Jun 23.
3
Immunogenicity of single dose live attenuated hepatitis a vaccine.
Indian Pediatr. 2011 Feb;48(2):135-7. doi: 10.1007/s13312-011-0039-4. Epub 2010 Nov 30.
4
Long-term immunogenicity of single dose of live attenuated hepatitis A vaccine in Indian children.
Indian Pediatr. 2015 Aug;52(8):687-90. doi: 10.1007/s13312-015-0697-8.
5
Comparison of immunogenicity between inactivated and live attenuated hepatitis A vaccines: a single-blind, randomized, parallel-group clinical trial among children in Xinjiang Uighur Autonomous Region, China.
Hum Vaccin Immunother. 2013 Jul;9(7):1460-5. doi: 10.4161/hv.24366. Epub 2013 Apr 9.
6
Long term follow-up study to evaluate immunogenicity and safety of a single dose of live attenuated hepatitis a vaccine in children.
Hum Vaccin Immunother. 2015;11(5):1147-52. doi: 10.4161/21645515.2014.979646.
7
Evaluation of immunogenicity and tolerability of a live attenuated hepatitis a vaccine in Indian children.
Indian Pediatr. 2006 Nov;43(11):983-7.
8
[Long-term immunogenicity and effectiveness of live attenuated hepatitis A vaccine (H2-strain)-a study on the result of 15 years' follow up].
Zhonghua Liu Xing Bing Xue Za Zhi. 2010 Dec;31(12):1332-5.
9
Persistent efficacy of live attenuated hepatitis A vaccine (H2-strain) after a mass vaccination program.
Chin Med J (Engl). 2005 Nov 20;118(22):1851-6.
10
Comparing live attenuated and inactivated hepatitis A vaccines: an immunogenicity study after one single dose.
Vaccine. 2011 Nov 8;29(48):9098-103. doi: 10.1016/j.vaccine.2011.08.078. Epub 2011 Aug 27.
引用本文的文献
1
Cellular immune response to a single dose of live attenuated hepatitis a virus vaccine in obese children and adolescents.
Heliyon. 2024 Aug 20;10(16):e36610. doi: 10.1016/j.heliyon.2024.e36610. eCollection 2024 Aug 30.
2
Identification of mutations in viral proteins involved in cell adaptation using a reverse genetic system of the live attenuated hepatitis A virus vaccine H2 strain.
Virol Sin. 2024 Dec;39(6):882-891. doi: 10.1016/j.virs.2024.08.004. Epub 2024 Aug 14.
3
Immunogenicity persistence of hepatitis A vaccines Healive® and Havrix® among children:15 years follow-up and long-term prediction.
Hum Vaccin Immunother. 2023 Aug 1;19(2):2227549. doi: 10.1080/21645515.2023.2227549. Epub 2023 Jun 26.
4
Recent Advances in Protective Vaccines against Hepatitis Viruses: A Narrative Review.
Viruses. 2023 Jan 12;15(1):214. doi: 10.3390/v15010214.
5
The infectivity and pathogenicity of hepatitis A virus live-attenuated vaccine strain H2 in type I interferon receptor-deficient mice.
Virol Sin. 2022 Oct;37(5):740-745. doi: 10.1016/j.virs.2022.07.009. Epub 2022 Jul 19.
6
Present and future management of viral hepatitis.
World J Gastroenterol. 2021 Dec 21;27(47):8081-8102. doi: 10.3748/wjg.v27.i47.8081.
7
Impact of Obesity and Being Overweight on the Immunogenicity to Live Attenuated Hepatitis A Vaccine in Children and Young Adults.
Vaccines (Basel). 2021 Feb 6;9(2):130. doi: 10.3390/vaccines9020130.
8
Hepatitis A vaccination and its immunological and epidemiological long-term effects - a review of the evidence.
Hum Vaccin Immunother. 2021 May 4;17(5):1496-1519. doi: 10.1080/21645515.2020.1819742. Epub 2020 Dec 16.
9
Hepatitis a virus infection in Central-West Tunisia: an age structured model of transmission and vaccination impact.
BMC Infect Dis. 2020 Aug 26;20(1):627. doi: 10.1186/s12879-020-05318-7.
10
Review of long term immunogenicity and tolerability of live hepatitis A vaccine.
Hum Vaccin Immunother. 2020 Nov 1;16(11):2816-2821. doi: 10.1080/21645515.2020.1741997. Epub 2020 Apr 3.
本文引用的文献
1
Long-term immunogenicity of single dose of live attenuated hepatitis A vaccine in Indian children.
Indian Pediatr. 2015 Aug;52(8):687-90. doi: 10.1007/s13312-015-0697-8.
2
Long term follow-up study to evaluate immunogenicity and safety of a single dose of live attenuated hepatitis a vaccine in children.
Hum Vaccin Immunother. 2015;11(5):1147-52. doi: 10.4161/21645515.2014.979646.
3
Indian Academy of Pediatrics (IAP) recommended immunization schedule for children aged 0 through 18 years--India, 2014 and updates on immunization.
Indian Pediatr. 2014 Oct;51(10):785-800. doi: 10.1007/s13312-014-0504-y.
4
A Mycobacterium bovis BCG-naked DNA prime-boost vaccination strategy induced CD4⁺ and CD8⁺ T-cell response against Mycobacterium tuberculosis immunogens.
J Immunol Res. 2014;2014:395626. doi: 10.1155/2014/395626. Epub 2014 Mar 11.
5
Development, production, and postmarketing surveillance of hepatitis A vaccines in China.
J Epidemiol. 2014;24(3):169-77. doi: 10.2188/jea.je20130022. Epub 2014 Mar 29.
6
Comparison of immunogenicity between inactivated and live attenuated hepatitis A vaccines: a single-blind, randomized, parallel-group clinical trial among children in Xinjiang Uighur Autonomous Region, China.
Hum Vaccin Immunother. 2013 Jul;9(7):1460-5. doi: 10.4161/hv.24366. Epub 2013 Apr 9.
7
WHO position paper on hepatitis A vaccines: June 2012-recommendations.
Vaccine. 2013 Jan 2;31(2):285-6. doi: 10.1016/j.vaccine.2012.10.102. Epub 2012 Nov 8.
8
WHO position paper on hepatitis A vaccines – June 2012.
Wkly Epidemiol Rec. 2012 Jul 13;87(28/29):261–76.
9
Changing pattern of hepatitis a virus epidemiology in an area of high endemicity.
Hepat Mon. 2012 Jun;12(6):382-5. doi: 10.5812/hepatmon.5940. Epub 2012 Jun 30.
10
Era of vaccination heralds a decline in incidence of hepatitis A in high-risk groups in China.
Hepat Mon. 2012 Feb;12(2):100-5. doi: 10.5812/hepatmon.838. Epub 2012 Feb 29.
Zotero 插件